• レポートコード:GIR-107A11948 • 出版社/出版日:GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態:英文、PDF、109ページ • 納品方法:Eメール(納期:2~3日) • 産業分類:医療 |
Single User | ¥522,000 (USD3,480) | ▷ お問い合わせ |
Multi User | ¥783,000 (USD5,220) | ▷ お問い合わせ |
Corporate User | ¥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、テノホビルアラフェナミド・その併用薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。テノホビルアラフェナミド・その併用薬の種類別市場規模(テノホビルアラフェナミド、エルビテグラビル/コビシスタット/エムトリシタビン/テノホビルアラフェナミド、エムトリシタビン/リルピビリン/テノホビルアラフェナミド、エムトリシタビン/レノホビルアラフェナミド、ビクテグラビル/エントリシタビン/テノホビルアラフェナミド)、用途別市場規模(病院、クリニック、ドラッグセンター、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・テノホビルアラフェナミド・その併用薬の市場概要 ・企業情報(企業概要、製品概要、販売量、価格、売上):Affine Formulations Limited、Beacon Pharmaceuticals、Biocon Limited、Cipla、Flamingo Pharmaceuticals Limited、Gilead Sciences、IPCA Laboratories、Johnson and Johnson、Julphar Bangladesh、Medisist Pharma、Mylan Pharmaceuticals、Natco Pharma、Sun Pharmaceutical Industries、CHIA TAI TIANQING (CTTQ) Pharmaceutical ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年:テノホビルアラフェナミド、エルビテグラビル/コビシスタット/エムトリシタビン/テノホビルアラフェナミド、エムトリシタビン/リルピビリン/テノホビルアラフェナミド、エムトリシタビン/レノホビルアラフェナミド、ビクテグラビル/エントリシタビン/テノホビルアラフェナミド ・用途別分析2016年-2026年:病院、クリニック、ドラッグセンター、その他 ・テノホビルアラフェナミド・その併用薬の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ ・テノホビルアラフェナミド・その併用薬のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア ・テノホビルアラフェナミド・その併用薬のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア ・テノホビルアラフェナミド・その併用薬の南米市場規模2016年-2026年:ブラジル、アルゼンチン ・テノホビルアラフェナミド・その併用薬の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Tenofovir Alafenamide and Its Combination Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Tenofovir Alafenamide and Its Combination Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Tenofovir Alafenamide and Its Combination Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Tenofovir Alafenamide and Its Combination Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Tenofovir Alafenamide
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
Emtricitabine/Rilpivirine/Tenofovir Alafenamide
Emtricitabine/Renofovir Alafenamide
Bictegravir/Emtricitabine/Tenofovir Alafenamide
Market segment by Application, can be divided into
Hospital
Clinic
Drug Center
Other
Market segment by players, this report covers
Affine Formulations Limited
Beacon Pharmaceuticals
Biocon Limited
Cipla
Flamingo Pharmaceuticals Limited
Gilead Sciences
IPCA Laboratories
Johnson and Johnson
Julphar Bangladesh
Medisist Pharma
Mylan Pharmaceuticals
Natco Pharma
Sun Pharmaceutical Industries
CHIA TAI TIANQING (CTTQ) Pharmaceutical
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Tenofovir Alafenamide and Its Combination Drugs
1.2 Classification of Tenofovir Alafenamide and Its Combination Drugs by Type
1.2.1 Overview: Global Tenofovir Alafenamide and Its Combination Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Type in 2020
1.2.3 Tenofovir Alafenamide
1.2.4 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
1.2.5 Emtricitabine/Rilpivirine/Tenofovir Alafenamide
1.2.6 Emtricitabine/Renofovir Alafenamide
1.2.7 Bictegravir/Emtricitabine/Tenofovir Alafenamide
1.3 Global Tenofovir Alafenamide and Its Combination Drugs Market by Application
1.3.1 Overview: Global Tenofovir Alafenamide and Its Combination Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global Tenofovir Alafenamide and Its Combination Drugs Market Size & Forecast
1.5 Global Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast by Region
1.5.1 Global Tenofovir Alafenamide and Its Combination Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Tenofovir Alafenamide and Its Combination Drugs Market Size by Region, (2016-2021)
1.5.3 North America Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Tenofovir Alafenamide and Its Combination Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Tenofovir Alafenamide and Its Combination Drugs Market Drivers
1.6.2 Tenofovir Alafenamide and Its Combination Drugs Market Restraints
1.6.3 Tenofovir Alafenamide and Its Combination Drugs Trends Analysis
2 Company Profiles
2.1 Affine Formulations Limited
2.1.1 Affine Formulations Limited Details
2.1.2 Affine Formulations Limited Major Business
2.1.3 Affine Formulations Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.1.4 Affine Formulations Limited Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Affine Formulations Limited Recent Developments and Future Plans
2.2 Beacon Pharmaceuticals
2.2.1 Beacon Pharmaceuticals Details
2.2.2 Beacon Pharmaceuticals Major Business
2.2.3 Beacon Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.2.4 Beacon Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Beacon Pharmaceuticals Recent Developments and Future Plans
2.3 Biocon Limited
2.3.1 Biocon Limited Details
2.3.2 Biocon Limited Major Business
2.3.3 Biocon Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.3.4 Biocon Limited Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Biocon Limited Recent Developments and Future Plans
2.4 Cipla
2.4.1 Cipla Details
2.4.2 Cipla Major Business
2.4.3 Cipla Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.4.4 Cipla Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Cipla Recent Developments and Future Plans
2.5 Flamingo Pharmaceuticals Limited
2.5.1 Flamingo Pharmaceuticals Limited Details
2.5.2 Flamingo Pharmaceuticals Limited Major Business
2.5.3 Flamingo Pharmaceuticals Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.5.4 Flamingo Pharmaceuticals Limited Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Flamingo Pharmaceuticals Limited Recent Developments and Future Plans
2.6 Gilead Sciences
2.6.1 Gilead Sciences Details
2.6.2 Gilead Sciences Major Business
2.6.3 Gilead Sciences Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.6.4 Gilead Sciences Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Gilead Sciences Recent Developments and Future Plans
2.7 IPCA Laboratories
2.7.1 IPCA Laboratories Details
2.7.2 IPCA Laboratories Major Business
2.7.3 IPCA Laboratories Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.7.4 IPCA Laboratories Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 IPCA Laboratories Recent Developments and Future Plans
2.8 Johnson and Johnson
2.8.1 Johnson and Johnson Details
2.8.2 Johnson and Johnson Major Business
2.8.3 Johnson and Johnson Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.8.4 Johnson and Johnson Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Johnson and Johnson Recent Developments and Future Plans
2.9 Julphar Bangladesh
2.9.1 Julphar Bangladesh Details
2.9.2 Julphar Bangladesh Major Business
2.9.3 Julphar Bangladesh Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.9.4 Julphar Bangladesh Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Julphar Bangladesh Recent Developments and Future Plans
2.10 Medisist Pharma
2.10.1 Medisist Pharma Details
2.10.2 Medisist Pharma Major Business
2.10.3 Medisist Pharma Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.10.4 Medisist Pharma Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Medisist Pharma Recent Developments and Future Plans
2.11 Mylan Pharmaceuticals
2.11.1 Mylan Pharmaceuticals Details
2.11.2 Mylan Pharmaceuticals Major Business
2.11.3 Mylan Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.11.4 Mylan Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Mylan Pharmaceuticals Recent Developments and Future Plans
2.12 Natco Pharma
2.12.1 Natco Pharma Details
2.12.2 Natco Pharma Major Business
2.12.3 Natco Pharma Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.12.4 Natco Pharma Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Natco Pharma Recent Developments and Future Plans
2.13 Sun Pharmaceutical Industries
2.13.1 Sun Pharmaceutical Industries Details
2.13.2 Sun Pharmaceutical Industries Major Business
2.13.3 Sun Pharmaceutical Industries Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.13.4 Sun Pharmaceutical Industries Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
2.14 CHIA TAI TIANQING (CTTQ) Pharmaceutical
2.14.1 CHIA TAI TIANQING (CTTQ) Pharmaceutical Details
2.14.2 CHIA TAI TIANQING (CTTQ) Pharmaceutical Major Business
2.14.3 CHIA TAI TIANQING (CTTQ) Pharmaceutical Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
2.14.4 CHIA TAI TIANQING (CTTQ) Pharmaceutical Tenofovir Alafenamide and Its Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 CHIA TAI TIANQING (CTTQ) Pharmaceutical Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Tenofovir Alafenamide and Its Combination Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Tenofovir Alafenamide and Its Combination Drugs Players Market Share
3.2.2 Top 10 Tenofovir Alafenamide and Its Combination Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Tenofovir Alafenamide and Its Combination Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Tenofovir Alafenamide and Its Combination Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Tenofovir Alafenamide and Its Combination Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Application (2016-2021)
5.2 Tenofovir Alafenamide and Its Combination Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
6.2 North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
6.3 North America Tenofovir Alafenamide and Its Combination Drugs Market Size by Country
6.3.1 North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2026)
6.3.2 United States Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
7.2 Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
7.3 Europe Tenofovir Alafenamide and Its Combination Drugs Market Size by Country
7.3.1 Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2026)
7.3.2 Germany Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7.3.3 France Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Market Size by Region
8.3.1 Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Region (2016-2026)
8.3.2 China Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.5 India Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
9.2 South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
9.3 South America Tenofovir Alafenamide and Its Combination Drugs Market Size by Country
9.3.1 South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Market Size by Country
10.3.1 Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Tenofovir Alafenamide and Its Combination Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Tenofovir Alafenamide and Its Combination Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Tenofovir Alafenamide and Its Combination Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Tenofovir Alafenamide and Its Combination Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Region (2021-2026)
Table 6. Affine Formulations Limited Corporate Information, Head Office, and Major Competitors
Table 7. Affine Formulations Limited Major Business
Table 8. Affine Formulations Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 9. Affine Formulations Limited Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Beacon Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Beacon Pharmaceuticals Major Business
Table 12. Beacon Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 13. Beacon Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Biocon Limited Corporate Information, Head Office, and Major Competitors
Table 15. Biocon Limited Major Business
Table 16. Biocon Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 17. Biocon Limited Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Cipla Corporate Information, Head Office, and Major Competitors
Table 19. Cipla Major Business
Table 20. Cipla Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 21. Cipla Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Flamingo Pharmaceuticals Limited Corporate Information, Head Office, and Major Competitors
Table 23. Flamingo Pharmaceuticals Limited Major Business
Table 24. Flamingo Pharmaceuticals Limited Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 25. Flamingo Pharmaceuticals Limited Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Gilead Sciences Corporate Information, Head Office, and Major Competitors
Table 27. Gilead Sciences Major Business
Table 28. Gilead Sciences Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 29. Gilead Sciences Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. IPCA Laboratories Corporate Information, Head Office, and Major Competitors
Table 31. IPCA Laboratories Major Business
Table 32. IPCA Laboratories Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 33. IPCA Laboratories Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Johnson and Johnson Corporate Information, Head Office, and Major Competitors
Table 35. Johnson and Johnson Major Business
Table 36. Johnson and Johnson Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 37. Johnson and Johnson Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Julphar Bangladesh Corporate Information, Head Office, and Major Competitors
Table 39. Julphar Bangladesh Major Business
Table 40. Julphar Bangladesh Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 41. Julphar Bangladesh Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Medisist Pharma Corporate Information, Head Office, and Major Competitors
Table 43. Medisist Pharma Major Business
Table 44. Medisist Pharma Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 45. Medisist Pharma Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Mylan Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 47. Mylan Pharmaceuticals Major Business
Table 48. Mylan Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 49. Mylan Pharmaceuticals Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Natco Pharma Corporate Information, Head Office, and Major Competitors
Table 51. Natco Pharma Major Business
Table 52. Natco Pharma Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 53. Natco Pharma Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Sun Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 55. Sun Pharmaceutical Industries Major Business
Table 56. Sun Pharmaceutical Industries Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 57. Sun Pharmaceutical Industries Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. CHIA TAI TIANQING (CTTQ) Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 59. CHIA TAI TIANQING (CTTQ) Pharmaceutical Major Business
Table 60. CHIA TAI TIANQING (CTTQ) Pharmaceutical Tenofovir Alafenamide and Its Combination Drugs Product and Solutions
Table 61. CHIA TAI TIANQING (CTTQ) Pharmaceutical Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Global Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million) by Players (2019-2021)
Table 63. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Share by Players (2019-2021)
Table 64. Breakdown of Tenofovir Alafenamide and Its Combination Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Tenofovir Alafenamide and Its Combination Drugs Players Head Office, Products and Services Provided
Table 66. Tenofovir Alafenamide and Its Combination Drugs Mergers & Acquisitions in the Past Five Years
Table 67. Tenofovir Alafenamide and Its Combination Drugs New Entrants and Expansion Plans
Table 68. Global Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million) by Type (2016-2021)
Table 69. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Share by Type (2016-2021)
Table 70. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Forecast by Type (2021-2026)
Table 71. Global Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2021)
Table 72. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Forecast by Application (2021-2026)
Table 73. North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2021) & (USD Million)
Table 74. North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2021-2026) & (USD Million)
Table 75. North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2021) & (USD Million)
Table 76. North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2021-2026) & (USD Million)
Table 77. North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2021) & (USD Million)
Table 78. North America Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2021-2026) & (USD Million)
Table 79. Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2021) & (USD Million)
Table 80. Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2021-2026) & (USD Million)
Table 81. Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2021) & (USD Million)
Table 82. Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2021-2026) & (USD Million)
Table 83. Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2021) & (USD Million)
Table 84. Europe Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2021-2026) & (USD Million)
Table 85. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2021) & (USD Million)
Table 86. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2021-2026) & (USD Million)
Table 87. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2021) & (USD Million)
Table 88. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2021-2026) & (USD Million)
Table 89. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Region (2016-2021) & (USD Million)
Table 90. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue by Region (2021-2026) & (USD Million)
Table 91. South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2021) & (USD Million)
Table 92. South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2021-2026) & (USD Million)
Table 93. South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2021) & (USD Million)
Table 94. South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2021-2026) & (USD Million)
Table 95. South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2021) & (USD Million)
Table 96. South America Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2021-2026) & (USD Million)
Table 97. Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2016-2021) & (USD Million)
Table 98. Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Type (2021-2026) & (USD Million)
Table 99. Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2016-2021) & (USD Million)
Table 100. Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Application (2021-2026) & (USD Million)
Table 101. Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2016-2021) & (USD Million)
Table 102. Middle East & Africa Tenofovir Alafenamide and Its Combination Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Tenofovir Alafenamide and Its Combination Drugs Picture
Figure 2. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Type in 2020
Figure 3. Tenofovir Alafenamide
Figure 4. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
Figure 5. Emtricitabine/Rilpivirine/Tenofovir Alafenamide
Figure 6. Emtricitabine/Renofovir Alafenamide
Figure 7. Bictegravir/Emtricitabine/Tenofovir Alafenamide
Figure 8. Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Application in 2020
Figure 9. Hospital Picture
Figure 10. Clinic Picture
Figure 11. Drug Center Picture
Figure 12. Other Picture
Figure 13. Global Tenofovir Alafenamide and Its Combination Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Tenofovir Alafenamide and Its Combination Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Region (2016-2026)
Figure 16. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Region in 2020
Figure 17. North America Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Tenofovir Alafenamide and Its Combination Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Tenofovir Alafenamide and Its Combination Drugs Market Drivers
Figure 23. Tenofovir Alafenamide and Its Combination Drugs Market Restraints
Figure 24. Tenofovir Alafenamide and Its Combination Drugs Market Trends
Figure 25. Affine Formulations Limited Recent Developments and Future Plans
Figure 26. Beacon Pharmaceuticals Recent Developments and Future Plans
Figure 27. Biocon Limited Recent Developments and Future Plans
Figure 28. Cipla Recent Developments and Future Plans
Figure 29. Flamingo Pharmaceuticals Limited Recent Developments and Future Plans
Figure 30. Gilead Sciences Recent Developments and Future Plans
Figure 31. IPCA Laboratories Recent Developments and Future Plans
Figure 32. Johnson and Johnson Recent Developments and Future Plans
Figure 33. Julphar Bangladesh Recent Developments and Future Plans
Figure 34. Medisist Pharma Recent Developments and Future Plans
Figure 35. Mylan Pharmaceuticals Recent Developments and Future Plans
Figure 36. Natco Pharma Recent Developments and Future Plans
Figure 37. Sun Pharmaceutical Industries Recent Developments and Future Plans
Figure 38. CHIA TAI TIANQING (CTTQ) Pharmaceutical Recent Developments and Future Plans
Figure 39. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Share by Players in 2020
Figure 40. Tenofovir Alafenamide and Its Combination Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 41. Global Top 3 Players Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share in 2020
Figure 42. Global Top 10 Players Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share in 2020
Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 44. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Share by Type in 2020
Figure 45. Global Tenofovir Alafenamide and Its Combination Drugs Market Share Forecast by Type (2021-2026)
Figure 46. Global Tenofovir Alafenamide and Its Combination Drugs Revenue Share by Application in 2020
Figure 47. Global Tenofovir Alafenamide and Its Combination Drugs Market Share Forecast by Application (2021-2026)
Figure 48. North America Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Type (2016-2026)
Figure 49. North America Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Application (2016-2026)
Figure 50. North America Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Country (2016-2026)
Figure 51. United States Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Canada Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Mexico Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Europe Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Type (2016-2026)
Figure 55. Europe Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Application (2016-2026)
Figure 56. Europe Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Country (2016-2026)
Figure 57. Germany Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. France Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. United Kingdom Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Russia Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Italy Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Type (2016-2026)
Figure 63. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Application (2016-2026)
Figure 64. Asia-Pacific Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Region (2016-2026)
Figure 65. China Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Japan Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South Korea Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. India Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Southeast Asia Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Australia Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. South America Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Type (2016-2026)
Figure 72. South America Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Application (2016-2026)
Figure 73. South America Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Country (2016-2026)
Figure 74. Brazil Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Argentina Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Middle East and Africa Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Type (2016-2026)
Figure 77. Middle East and Africa Tenofovir Alafenamide and Its Combination Drugs Sales Market Share by Application (2016-2026)
Figure 78. Middle East and Africa Tenofovir Alafenamide and Its Combination Drugs Revenue Market Share by Country (2016-2026)
Figure 79. Turkey Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Saudi Arabia Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. UAE Tenofovir Alafenamide and Its Combination Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. Methodology
Figure 83. Research Process and Data Source